Open AccessEfficacy of Ibutilide for Terminating Recent Onset Atrial Fibrillation- A Single Centre Study
Author(s) -
M S Soumya,
SK. Khasim,
Ravinder Reddy Kasturi,
Srinivas Kumar Arramraju,
Nikhil Mudgalkar,
Ashish Baviskar
Publication year - 2021
Publication title -
perspectives in medical research
Language(s) - English
Resource type - Journals
eISSN - 2348-229X
pISSN - 2348-1447
DOI - 10.47799/pimr.0902.16
Subject(s) - ibutilide , atrial fibrillation , medicine , cardiology , adverse effect , medical record , anesthesia , atrial flutter
Ibutilide is a class 3 antiarrythmic agent that is usedinfrequently. There are few studies on its usage, especiallyamong Indians.Materials & Methods: A retrospective study was conductedon patients in a tertiary care unit who had recently developedatrial fibrillation and were given the normal dose of ibutilide.During the study period, data was gathered from medicalrecords.Results: During the study period, ibutilide was given to a totalof 40 patients who met the inclusion criteria. The majority ofthe participants were under 60 years old and had only been inatrial fibrillation for less than 24 hours. In 70% of cases, atrialfibrillation could be successfully terminated with only a smallrisk of adverse events.Conclusion: Ibutilide is a safe and effective treatment forpeople who have recent onset atrial fibrillation.